Item	Item No	Recommendation	Page Number
Title and abstract	1	(a) Indicate the study's design with a commonly used term	3
		in the title or the abstract	
		(b) Provide in the abstract an informative and balanced	3-4
		summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	6-7
		investigation being reported	
Objectives	3	State specific objectives, including any prespecified	7 and 10
		hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates,	8
		including periods of recruitment, exposure, follow-up, and	
		data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and	8-9
		methods of selection of participants. Describe methods of	
		follow-up	
		(b) For matched studies, give matching criteria and	N/A
		number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors,	9-10
		potential confounders, and effect modifiers. Give	
		diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and	9-10
measurement		details of methods of assessment (measurement). Describe	
		comparability of assessment methods if there is more than	
		one group	
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	9, 10, flow diagram in supplementary data
Quantitative variables	11	Explain how quantitative variables were handled in the	10-11
		analyses. If applicable, describe which groupings were	
		chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used	10-11
		to control for confounding	
		(b) Describe any methods used to examine subgroups and	10-11
		interactions	
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, explain how loss to follow-up was	N/A
		addressed	
		( <u>e</u> ) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—	11, supplementary data
		eg numbers potentially eligible, examined for eligibility,	flow diagram
		confirmed eligible, included in the study, completing	
		communed engible, included in the study, completing	

## STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

		follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	Supplementary data
		(c) Consider use of a flow diagram	Supplementary data
Descriptive data	14*	(a) Give characteristics of study participants (eg	12 and supplementary
		demographic, clinical, social) and information on	data
		exposures and potential confounders	
		(b) Indicate number of participants with missing data for	N/A
		each variable of interest	
		(c) Summarise follow-up time (eg, average and total	N/A
		amount)	
Outcome data	15*	Report numbers of outcome events or summary measures	12-14, figures, tables
		over time	and supplementary
			data
Main results	16	(a) Give unadjusted estimates and, if applicable,	11-15, figures, tables
		confounder-adjusted estimates and their precision (eg,	and supplementary
		95% confidence interval). Make clear which confounders	data
		were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables	N/A
		were categorized	
		(c) If relevant, consider translating estimates of relative	N/A
		risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and	Supplementary data
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	17-18
Limitations	19	Discuss limitations of the study, taking into account	21-22
		sources of potential bias or imprecision. Discuss both	
		direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results	17-22
		considering objectives, limitations, multiplicity of	
		analyses, results from similar studies, and other relevant	
		evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study	17-22
		results	
Other information			
Funding	22	Give the source of funding and the role of the funders for	2
		the present study and, if applicable, for the original study	
		on which the present article is based	

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.